Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine Infusion in Pancreatic Cancer
NCT04048278Phase 1Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2018
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in pancreatic cancer (PC) (2 arms), sponsored by University of Illinois Chicago. Primary endpoints: Specimen outcome measure: Enzymatic Activity, Specimen outcome measure: Number of CTCs and 1 more. Started Nov 2018; status: recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04048278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04048278.